Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CBMG NASDAQ:EIGR NASDAQ:IPHA OTCMKTS:IPHYF NASDAQ:OCGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBMGCellular Biomedicine Group$19.68$11.48▼$19.75$384.69M1.35129,776 shs8,375 shsEIGREiger BioPharmaceuticals$4.35$1.10▼$43.35$2.55M1.83103,866 shs137,800 shsIPHAInnate Pharma$1.81+5.2%$2.03$1.29▼$3.51$158.54M0.21186,621 shs12,591 shsIPHYFInnate Pharma$1.31$1.57$1.31▼$1.95$109.82M0.588 shsN/AOCGNOcugen$1.15+1.8%$0.93$0.52▼$1.98$329.99M4.184.58 million shs5.58 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBMGCellular Biomedicine Group0.00%0.00%0.00%0.00%0.00%EIGREiger BioPharmaceuticals0.00%0.00%0.00%0.00%0.00%IPHAInnate Pharma+5.23%-0.60%-8.59%-3.47%-16.20%IPHYFInnate Pharma0.00%-32.82%-9.66%-9.66%-32.13%OCGNOcugen+1.77%+19.05%+1.77%+66.57%-36.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBMGCellular Biomedicine GroupN/AN/AN/AN/AN/AN/AN/AN/AEIGREiger BioPharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIPHAInnate Pharma2.6003 of 5 stars3.85.00.00.00.01.70.0IPHYFInnate PharmaN/AN/AN/AN/AN/AN/AN/AN/AOCGNOcugen0.9458 of 5 stars3.51.00.00.00.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBMGCellular Biomedicine Group 0.00N/AN/AN/AEIGREiger BioPharmaceuticals 0.00N/AN/AN/AIPHAInnate Pharma 3.50Strong Buy$11.00507.73% UpsideIPHYFInnate Pharma 0.00N/AN/AN/AOCGNOcugen 3.00Buy$6.00421.74% UpsideCurrent Analyst Ratings BreakdownLatest CBMG, EIGR, OCGN, IPHYF, and IPHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.006/24/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.005/12/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.005/12/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/24/2025IPHAInnate PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.50 ➝ $11.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBMGCellular Biomedicine Group$340K0.00N/AN/A$2.89 per share0.00EIGREiger BioPharmaceuticals$15.77M0.00N/AN/A$37.68 per share0.00IPHAInnate Pharma$21.77M7.66N/AN/A$0.11 per share16.45IPHYFInnate Pharma$21.77M5.04N/AN/A$0.11 per share11.91OCGNOcugen$4.05M82.92N/AN/A$0.10 per share11.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBMGCellular Biomedicine Group-$49.98MN/AN/AN/AN/AN/A-144.80%-61.68%N/AEIGREiger BioPharmaceuticals-$96.78M-$59.16N/AN/AN/A-590.80%-332.49%-99.77%N/AIPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/A9/17/2025 (Estimated)IPHYFInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/A9/17/2025 (Estimated)OCGNOcugen-$54.05M-$0.19N/AN/AN/A-1,271.12%-223.00%-92.20%8/14/2025 (Estimated)Latest CBMG, EIGR, OCGN, IPHYF, and IPHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025OCGNOcugen-$0.06-$0.05+$0.01-$0.05N/A$1.48 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBMGCellular Biomedicine GroupN/AN/AN/AN/AN/AEIGREiger BioPharmaceuticalsN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/AIPHYFInnate PharmaN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBMGCellular Biomedicine GroupN/A0.470.47EIGREiger BioPharmaceuticalsN/A3.313.24IPHAInnate Pharma2.522.602.60IPHYFInnate PharmaN/A2.602.60OCGNOcugen1.742.602.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBMGCellular Biomedicine Group21.98%EIGREiger BioPharmaceuticals62.46%IPHAInnate Pharma0.16%IPHYFInnate PharmaN/AOCGNOcugen10.27%Insider OwnershipCompanyInsider OwnershipCBMGCellular Biomedicine Group8.50%EIGREiger BioPharmaceuticals4.22%IPHAInnate Pharma31.89%IPHYFInnate Pharma31.89%OCGNOcugen4.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBMGCellular Biomedicine Group21719.48 millionN/AOptionableEIGREiger BioPharmaceuticals561.48 million1.42 millionOptionableIPHAInnate Pharma22092.18 million62.78 millionNot OptionableIPHYFInnate Pharma17983.83 million57.10 millionNot OptionableOCGNOcugen80292.03 million279.12 millionOptionableCBMG, EIGR, OCGN, IPHYF, and IPHA HeadlinesRecent News About These CompaniesOcugen's (OCGN) "Buy" Rating Reaffirmed at HC WainwrightJune 24, 2025 | marketbeat.comOcugen (NASDAQ:OCGN) Given "Buy" Rating at Chardan CapitalJune 24, 2025 | marketbeat.comCarisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic DiseasesJune 23, 2025 | globenewswire.comOcugen: Three Potential Gene-Therapy Filings By 2028June 18, 2025 | seekingalpha.comOcugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt DiseaseJune 17, 2025 | msn.comOcugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate ...June 16, 2025 | gurufocus.comOcugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt DiseaseJune 16, 2025 | globenewswire.comBank of America Corp DE Sells 583,634 Shares of Ocugen, Inc. (NASDAQ:OCGN)June 14, 2025 | marketbeat.comOcugen, Inc. to Present at 2025 BIO International Convention, Showcasing Gene Therapy Advancements for Blindness DiseasesJune 11, 2025 | quiverquant.comQOcugen To Present at BIO International Convention 2025June 11, 2025 | globenewswire.comOcugen signs binding term sheet for license of OCU400 modifier gene therapy for retinitis pigmentosa in KoreaJune 7, 2025 | pharmabiz.comPOcugen Secures Licensing Agreement for OCU400 in KoreaJune 6, 2025 | msn.comOcugen signs term sheet for korean licensing of OCU400 gene therapyJune 5, 2025 | ophthalmologytimes.comOOcugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in KoreaJune 5, 2025 | globenewswire.comOcugen’s OCU410ST receives Rare Pediatric Disease Designation for the treatment of ABCA4-associated retinopathiesMay 27, 2025 | ophthalmologytimes.comOOcugen wins FDA rare pediatric disease status for genetic eye disorder treatmentMay 27, 2025 | msn.comOcugen, Inc. Receives FDA Rare Pediatric Disease Designation for OCU410ST in Treatment of ABCA4-Associated RetinopathiesMay 27, 2025 | quiverquant.comQOcugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt DiseaseMay 27, 2025 | globenewswire.comThe Analyst Verdict: Ocugen In The Eyes Of 5 ExpertsMay 14, 2025 | nasdaq.comOcugen Reports Progress in Q1 2025 with Advancements in Gene TherapyMay 13, 2025 | msn.com1OCGN : The Analyst Verdict: Ocugen In The Eyes Of 5 ExpertsMay 13, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCBMG, EIGR, OCGN, IPHYF, and IPHA Company DescriptionsCellular Biomedicine Group NASDAQ:CBMGCellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.Eiger BioPharmaceuticals NASDAQ:EIGREiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.Innate Pharma NASDAQ:IPHA$1.81 +0.09 (+5.23%) Closing price 07/10/2025 03:59 PM EasternExtended Trading$1.75 -0.06 (-3.54%) As of 05:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Innate Pharma OTCMKTS:IPHYF$1.31 0.00 (0.00%) As of 07/9/2025Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Ocugen NASDAQ:OCGN$1.15 +0.02 (+1.77%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$1.14 -0.01 (-0.87%) As of 07:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
